1. Home
  2. GCMG vs ZVRA Comparison

GCMG vs ZVRA Comparison

Compare GCMG & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GCM Grosvenor Inc.

GCMG

GCM Grosvenor Inc.

HOLD

Current Price

$12.95

Market Cap

805.6M

Sector

Finance

ML Signal

HOLD

Logo Zevra Therapeutics Inc.

ZVRA

Zevra Therapeutics Inc.

HOLD

Current Price

$11.12

Market Cap

689.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GCMG
ZVRA
Founded
1971
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
805.6M
689.4M
IPO Year
2020
2015

Fundamental Metrics

Financial Performance
Metric
GCMG
ZVRA
Price
$12.95
$11.12
Analyst Decision
Buy
Strong Buy
Analyst Count
3
5
Target Price
$14.33
★ $23.00
AVG Volume (30 Days)
414.0K
★ 769.8K
Earning Date
05-07-2026
05-06-2026
Dividend Yield
★ 4.48%
N/A
EPS Growth
★ 1300.00
159.21
EPS
0.17
★ 0.74
Revenue
★ $557,565,000.00
$106,470,000.00
Revenue This Year
$7.28
$37.27
Revenue Next Year
$11.70
$53.42
P/E Ratio
$74.29
★ $15.22
Revenue Growth
8.47
★ 350.91
52 Week Low
$9.30
$8.01
52 Week High
$14.87
$15.04

Technical Indicators

Market Signals
Indicator
GCMG
ZVRA
Relative Strength Index (RSI) 48.20 37.77
Support Level $11.25 $10.81
Resistance Level $13.94 $12.19
Average True Range (ATR) 0.34 0.43
MACD -0.01 -0.11
Stochastic Oscillator 58.33 4.76

Price Performance

Historical Comparison
GCMG
ZVRA

About GCMG GCM Grosvenor Inc.

GCM Grosvenor Inc is a world-wide alternative asset management firm. It invests on behalf of clients who seek allocations to alternative investments, such as private equity, infrastructure, real estate, credit, ESG, and absolute return strategies. The company invests maximum in Private Equity. The company's offerings include multi-manager portfolios as well as portfolios of direct investments and co-investments.

About ZVRA Zevra Therapeutics Inc.

Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.

Share on Social Networks: